Rabbit Anti-IL27A Polyclonal Antibody#abs133076

abs133076-100ug

1-2 Weeks

301.0

abs133076-50ug

1-2 Weeks

201.0

catalog

Description

IL-27 is a cytokine that exhibits both pro-inflammatory and anti-inflammatory properties. It plays a crucial role in regulating the development of T helper cells and has various effects on innate immune cells. The primary target cells of IL-27 are CD4 T helper cells, which can differentiate into different types of effector cells, including TH1, TH2, and TH17.
One of the key functions of IL-27 is its ability to suppress T-cell proliferation and induce cytotoxic T-cell activity. It also plays a role in stimulating isotype switching in B-cells. Furthermore, IL-27 has a significant impact on CD4 T-cell expansion, particularly naive cells.
IL-27 works synergistically with IL-12 to trigger the production of interferon-gamma (IFN-gamma) in naive CD4 T-cells. It binds to the cytokine receptor WSX-1/TCCR, which is necessary for IL-27-mediated signal transduction. Moreover, IL-27 potentiates the early phase of TH1 response while suppressing TH2 and TH17 differentiation.
The differentiation of TH1 cells is induced by IL-27 through two distinct pathways: the p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also leads to phosphorylation of STAT1, STAT3, STAT4, and STAT5, activating TBX21/T-Bet via STAT1. This activation results in the up-regulation of IL12RB2, which is critical for TH1 cell commitment. Additionally, IL-27 suppresses the expression of GATA3, an inhibitor of TH1 cell development.
In CD8 T-cells, IL-27 activates STATs and GZMB. Interestingly, IL-27 has a potent inhibitory effect on the development and production of IL-17 by TH17 cells. Even the IL-27 subunit p28 alone can inhibit IL-17 production by both CD4 and CD8 T-cells.
While IL-27 suppresses the development of pro-inflammatory TH17 cells through STAT1, it inhibits the development of anti-inflammatory regulatory T-cells (iTreg) independently of STAT1. Additionally, IL-27 has suppressive effects on pro-inflammatory cytokine production such as IL2, IL4, IL5, and IL6. It activates suppressors of cytokine signaling like SOCS1 and SOCS3. Furthermore, IL-27 can counteract the effects of certain cytokines, such as IL6, directly on T cells.
IL-27 also displays important antitumor and antiangiogenic activities. It activates the production of antiangiogenic chemokines like IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, IL-27 induces IRF1/interferon regulatory factor 1 and up-regulates the expression of MHC class II transactivator/CIITA, resulting in the up-regulation of major histocompatibility complex class II. Additionally, IL-27 exhibits antiviral activity by inhibiting HIV-1 replication.

Concentration

1mg/ml

Target

Background

Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR which appears to be required but not sufficient for IL-27-mediated signal transduction. IL-27 potentiate the early phase of TH1 response and suppress TH2 and TH17 differentiation. It induces the differentiation of TH1 cells via two distinct pathways, p38 MAPK/TBX21- and ICAM1/ITGAL/ERK-dependent pathways. It also induces STAT1, STAT3, STAT4 and STAT5 phosphorylation and activates TBX21/T-Bet via STAT1 with resulting IL12RB2 up-regulation, an event crucial to TH1 cell commitment. It suppresses the expression of GATA3, the inhibitor TH1 cells development. In CD8 T-cells, it activates STATs as well as GZMB. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. Indeed IL27 alone is also able to inhibit the production of IL17 by CD4 and CD8 T-cells. While IL-27 suppressed the development of proinflammatory Th17 cells via STAT1, it inhibits the development of anti-inflammatory inducible regulatory T-cells, iTreg, independently of STAT1. IL-27 has also an effect on cytokine production, it suppresses proinflammatory cytokine production such as IL2, IL4, IL5 and IL6 and activates suppressors of cytokine signaling such as SOCS1 and SOCS3. Apart from suppression of cytokine production, IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T-cells. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines such as IP-10/CXCL10 and MIG/CXCL9. In vein endothelial cells, it induces IRF1/interferon regulatory factor 1 and increase the expression of MHC class II transactivator/CIITA with resulting up-regulation of major histocompatibility complex class II. IL-27 also demonstrates antiviral activity with inhibitory properties on HIV-1 replication.